Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

HIV-host interactome revealed directly from infected cells.

Luo Y, Jacobs EY, Greco TM, Mohammed KD, Tong T, Keegan S, Binley JM, Cristea IM, Fenyö D, Rout MP, Chait BT, Muesing MA.

Nat Microbiol. 2016 Jul;1(7). pii: 16068. Epub 2016 May 23.

2.

Improving Loop Modeling of the Antibody Complementarity-Determining Region 3 Using Knowledge-Based Restraints.

Finn JA, Koehler Leman J, Willis JR, Cisneros A 3rd, Crowe JE Jr, Meiler J.

PLoS One. 2016 May 16;11(5):e0154811. doi: 10.1371/journal.pone.0154811. eCollection 2016.

3.

Quantitative Correlation between Infectivity and Gp120 Density on HIV-1 Virions Revealed by Optical Trapping Virometry.

DeSantis MC, Kim JH, Song H, Klasse PJ, Cheng W.

J Biol Chem. 2016 Jun 17;291(25):13088-97. doi: 10.1074/jbc.M116.729210. Epub 2016 Apr 25.

PMID:
27129237
4.

Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability.

Mason RD, Welles HC, Adams C, Chakrabarti BK, Gorman J, Zhou T, Nguyen R, O'Dell S, Lusvarghi S, Bewley CA, Li H, Shaw GM, Sheng Z, Shapiro L, Wyatt R, Kwong PD, Mascola JR, Roederer M.

PLoS Pathog. 2016 Apr 11;12(4):e1005537. doi: 10.1371/journal.ppat.1005537. eCollection 2016 Apr. Erratum in: PLoS Pathog. 2016 May;12(5):e1005674.

5.

High-Resolution Longitudinal Study of HIV-1 Env Vaccine-Elicited B Cell Responses to the Virus Primary Receptor Binding Site Reveals Affinity Maturation and Clonal Persistence.

Wang Y, Sundling C, Wilson R, O'Dell S, Chen Y, Dai K, Phad GE, Zhu J, Xiao Y, Mascola JR, Karlsson Hedestam GB, Wyatt RT, Li Y.

J Immunol. 2016 May 1;196(9):3729-43. doi: 10.4049/jimmunol.1502543. Epub 2016 Mar 21.

PMID:
27001953
6.

Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response.

Shcherbakov DN, Bakulina AY, Karpenko LI, Ilyichev AA.

Acta Naturae. 2015 Oct-Dec;7(4):11-21.

7.

A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.

Freund NT, Horwitz JA, Nogueira L, Sievers SA, Scharf L, Scheid JF, Gazumyan A, Liu C, Velinzon K, Goldenthal A, Sanders RW, Moore JP, Bjorkman PJ, Seaman MS, Walker BD, Klein F, Nussenzweig MC.

PLoS Pathog. 2015 Oct 30;11(10):e1005238. doi: 10.1371/journal.ppat.1005238. eCollection 2015 Oct.

8.

Immune correlates of vaccine protection against HIV-1 acquisition.

Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS.

Sci Transl Med. 2015 Oct 21;7(310):310rv7. doi: 10.1126/scitranslmed.aac7732. Review.

9.

Phenotypic Correlates of HIV-1 Macrophage Tropism.

Arrildt KT, LaBranche CC, Joseph SB, Dukhovlinova EN, Graham WD, Ping LH, Schnell G, Sturdevant CB, Kincer LP, Mallewa M, Heyderman RS, Rie AV, Cohen MS, Spudich S, Price RW, Montefiori DC, Swanstrom R.

J Virol. 2015 Nov;89(22):11294-311. doi: 10.1128/JVI.00946-15. Epub 2015 Sep 2.

10.

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.

Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, DeZure A, Lynch RM, Gordon I, Plummer S, Hendel CS, Pegu A, Conan-Cibotti M, Sitar S, Bailer RT, Narpala S, McDermott A, Louder M, O'Dell S, Mohan S, Pandey JP, Schwartz RM, Hu Z, Koup RA, Capparelli E, Mascola JR, Graham BS; VRC 602 Study Team.

Clin Exp Immunol. 2015 Dec;182(3):289-301. doi: 10.1111/cei.12692. Epub 2015 Sep 24.

PMID:
26332605
11.

A Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV Immunogen.

Vijayan A, García-Arriaza J, Raman SC, Conesa JJ, Chichón FJ, Santiago C, Sorzano CÓ, Carrascosa JL, Esteban M.

PLoS One. 2015 Jul 24;10(7):e0133595. doi: 10.1371/journal.pone.0133595. eCollection 2015.

12.

South African HIV-1 subtype C transmitted variants with a specific V2 motif show higher dependence on α4β7 for replication.

Richardson SI, Gray ES, Mkhize NN, Sheward DJ, Lambson BE, Wibmer CK, Masson L, Werner L, Garrett N, Passmore JA, Karim QA, Karim SS, Williamson C, Moore PL, Morris L.

Retrovirology. 2015 Jun 24;12:54. doi: 10.1186/s12977-015-0183-3.

13.

Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.

Kilgore KM, Murphy MK, Burton SL, Wetzel KS, Smith SA, Xiao P, Reddy S, Francella N, Sodora DL, Silvestri G, Cole KS, Villinger F, Robinson JE, Pulendran B, Hunter E, Collman RG, Amara RR, Derdeyn CA.

J Virol. 2015 Aug;89(16):8130-51. doi: 10.1128/JVI.01221-14. Epub 2015 May 27.

14.

Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.

Gombos RB, Kolodkin-Gal D, Eslamizar L, Owuor JO, Mazzola E, Gonzalez AM, Korioth-Schmitz B, Gelman RS, Montefiori DC, Haynes BF, Schmitz JE.

J Virol. 2015 Aug;89(15):7813-28. doi: 10.1128/JVI.00783-15. Epub 2015 May 20.

15.

Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.

Phad GE, Vázquez Bernat N, Feng Y, Ingale J, Martinez Murillo PA, O'Dell S, Li Y, Mascola JR, Sundling C, Wyatt RT, Karlsson Hedestam GB.

J Immunol. 2015 Jun 15;194(12):5903-14. doi: 10.4049/jimmunol.1500122. Epub 2015 May 11.

16.

Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.

Barbian HJ, Decker JM, Bibollet-Ruche F, Galimidi RP, West AP Jr, Learn GH, Parrish NF, Iyer SS, Li Y, Pace CS, Song R, Huang Y, Denny TN, Mouquet H, Martin L, Acharya P, Zhang B, Kwong PD, Mascola JR, Verrips CT, Strokappe NM, Rutten L, McCoy LE, Weiss RA, Brown CS, Jackson R, Silvestri G, Connors M, Burton DR, Shaw GM, Nussenzweig MC, Bjorkman PJ, Ho DD, Farzan M, Hahn BH.

MBio. 2015 Apr 21;6(2). pii: e00296-15. doi: 10.1128/mBio.00296-15.

17.

Cleavage-independent HIV-1 Env trimers engineered as soluble native spike mimetics for vaccine design.

Sharma SK, de Val N, Bale S, Guenaga J, Tran K, Feng Y, Dubrovskaya V, Ward AB, Wyatt RT.

Cell Rep. 2015 Apr 28;11(4):539-50. doi: 10.1016/j.celrep.2015.03.047. Epub 2015 Apr 16.

18.

Comprehensive antigenic map of a cleaved soluble HIV-1 envelope trimer.

Derking R, Ozorowski G, Sliepen K, Yasmeen A, Cupo A, Torres JL, Julien JP, Lee JH, van Montfort T, de Taeye SW, Connors M, Burton DR, Wilson IA, Klasse PJ, Ward AB, Moore JP, Sanders RW.

PLoS Pathog. 2015 Mar 25;11(3):e1004767. doi: 10.1371/journal.ppat.1004767. eCollection 2015 Mar.

19.

CD4 binding site broadly neutralizing antibody selection of HIV-1 escape mutants.

Dreja H, Pade C, Chen L, McKnight Á.

J Gen Virol. 2015 Jul;96(Pt 7):1899-905. doi: 10.1099/vir.0.000120. Epub 2015 Mar 11.

20.

Antibody engineering for increased potency, breadth and half-life.

Sievers SA, Scharf L, West AP Jr, Bjorkman PJ.

Curr Opin HIV AIDS. 2015 May;10(3):151-9. doi: 10.1097/COH.0000000000000148. Review.

Items per page

Supplemental Content

Write to the Help Desk